Omnicell (NASDAQ:OMCL) Updates Q1 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its first quarter 2025 earnings guidance on Thursday. The company provided EPS guidance of 0.150-0.250 for the period, compared to the consensus EPS estimate of 0.310. The company issued revenue guidance of $255.0 million-$265.0 million, compared to the consensus revenue estimate of $264.9 million. Omnicell also updated its FY 2025 guidance to 1.650-1.850 EPS.

Omnicell Trading Up 2.0 %

Shares of OMCL stock traded up $0.78 during mid-day trading on Friday, reaching $40.21. The stock had a trading volume of 369,396 shares, compared to its average volume of 369,290. Omnicell has a 1-year low of $25.12 and a 1-year high of $55.74. The firm has a market cap of $1.86 billion, a price-to-earnings ratio of -103.01, a PEG ratio of 30.78 and a beta of 0.78. The business’s fifty day moving average is $44.34 and its 200-day moving average is $43.20.

Omnicell (NASDAQ:OMCL) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a positive return on equity of 2.55% and a negative net margin of 1.66%. On average, analysts forecast that Omnicell will post 0.94 earnings per share for the current year.

Wall Street Analyst Weigh In

OMCL has been the subject of several recent research reports. JPMorgan Chase & Co. lifted their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a report on Thursday, November 21st. Bank of America cut their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research note on Monday, January 6th. Benchmark reiterated a “buy” rating and set a $62.00 price target on shares of Omnicell in a research report on Tuesday. StockNews.com cut Omnicell from a “buy” rating to a “hold” rating in a research report on Tuesday, December 10th. Finally, Craig Hallum increased their target price on Omnicell from $45.00 to $64.00 and gave the company a “buy” rating in a research report on Thursday, October 31st. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $52.33.

Insider Buying and Selling

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the firm’s stock in a transaction on Tuesday, December 10th. The stock was sold at an average price of $47.30, for a total value of $567,600.00. Following the completion of the sale, the director now directly owns 58,427 shares of the company’s stock, valued at $2,763,597.10. This trade represents a 17.04 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 2.64% of the stock is owned by company insiders.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.